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Abstract  
Introduction: In addition to arteriovenous fistula, patients on hemodialysis often have risks 
that potentially increase cardiac output (CO) such as anemia, fluid retention, and multiple 
vasodilator use, contributing to increased risk of high output heart failure. The aims of this 
study were to determine the relationships between these factors and increased CO and to 
evaluate the effects of the high output state on ventricular morphology, dysfunction, and 
myocardial energetics in patients receiving hemodialysis, using noninvasive pressure-volume 
loop assessment. 
Methods: Cardiovascular function were assessed in hemodialysis patients with high output 
(EF≥50%, cardiac index [CI] >3.5L/min/m2, n=30), those with normal output (CI ≤3.5L/min/m2, 
n=205), and control subjects without ESRD (n=155).  
Results:  As compared to control subjects and hemodialysis patients with normal output, 
those with elevated output displayed decreased systemic vascular resistance (SVR) and 
higher ventricular contractility and heart rate. Lower hemoglobin levels were correlated with 
decreased SVR, greater LV contractility, and tachycardia while estimated plasma volume and 
inter-dialytic weight gain were associated with increased ventricular preload (end-diastolic 
volume), thus increasing CO. Patients with high output displayed markedly increased 
pressure-volume area (PVA) and PVA/stroke volume ratio, that were correlated directly with 
increased CO, suggesting a contribution of high output state to greater myocardial oxygen 
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consumption and cardiac energy costs. The use of combination vasodilator therapy 
(angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker and calcium channel 
blocker) was not associated with high output states.  
Conclusion:  These data provide new insights into the mechanisms underlying high output 
states in patients on dialysis. 
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Introduction  
 Heart failure (HF) is common and remains the leading cause of morbidity and 
mortality in patients with end stage renal disease (ESRD) on dialysis.[1] Cardiac output (CO) 
is usually low or normal in HF but a minority of patients have a high output state, which is 
termed high output HF.[2] The literature on high output HF in dialysis patients is limited to 
reviews and case reports mainly focusing on arteriovenous fistula (AVF).[3-5] It is well known 
that AVF decreases systemic vascular resistance (SVR) and simultaneously increases 
venous return to the heart, thus increasing CO.[6, 7] Besides AVF, hemodialysis patients 
often have conditions that potentially increase CO, such as fluid retention, renal anemia, and 
multiple vasodilator use. However, little is known how these factors contribute to high output 
states in this population. 
A recent study has shown that arteriovenous shunt-related high output HF is 
associated with substantial risk of death.[2] The high output state may lead to cardiac 
remodeling and myocardial dysfunction that are believed to increase myocardial oxygen 
demands and cardiac energy costs, leading to morbidity and mortality in patients with 
hemodialysis. However, very little information is available regarding how elevated CO might 
alter ventricular structure, function, myocardial oxygen consumption, and energy costs in 
patients on dialysis. The pressure-volume loop assessment provides detailed information on 
cardiovascular function, including left ventricular (LV) contractility, arterial afterload, preload, 
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and myocardial energetics, and its utility in dialysis patients has been shown recently (Figure 
1).[8, 9] Accordingly, the aims of the present study were (1) to elucidate relationships among 
fluid retention, anemia, vasodilator use, and increased CO; and (2) to determine the effects 
of high output states on ventricular morphology, dysfunction, and myocardial energetics in 
patients receiving hemodialysis. 
 
Methods  
Study population 
Study participants were recruited from patients receiving hemodialysis treatment at 
Hidaka Hospital (Takasaki, Japan) and Gunma University Hospital (Maebashi, Japan). Some 
participant data from this study has been previously published,[8-10] but not as it relates to 
the association between CO and cardiovascular function. All subjects were hemodynamically 
stable and hemodialysis was performed 3 times weekly via AVFs (3-5h/day). Among 289 
patients who agreed to participate in this study, we excluded patients with moderate or severe 
left heart valvular disease (n=14), low EF (EF<50%; n=24), severe anemia (hemoglobin<8.0 
g/dl; n=1), no simultaneous blood pressure (BP) measurements (n=5), and poor 
echocardiographic images (n=10), remaining 235 subjects for final analyses. No participant 
had other alternative causes of high CO, either physiologic (pregnancy, fever, infection), 
congenital, or metabolic diseases. To investigate the characteristics of high output 
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hemodialysis patients, we categorized participants according to cardiac index (CI). Given the 
well-known overestimation of stroke volume (SV) by pulse Doppler echocardiography, high 
output state was defined by CI >3.5 L/min*m2, and normal output was defined by CI ≤3.5 
L/min*m2, as previously reported.[2] Control subjects who not receiving hemodialysis were 
recruited from the echocardiographic laboratory database at the Gunma University Hospital 
as a comparator group (n=155). They were required to have normal EF and no left heart 
valvular heart disease at the echocardiographic examination (criteria above). The study 
protocol was approved by the institutional medical ethics committees of the two hospitals and 
written informed consent was obtained from all participants.   
Clinical assessment  
Demographic characteristics, medications, and clinical variables related to the 
delivery of hemodialysis were abstracted from the medical records. Blood samples were 
collected before starting dialysis sessions. Plasma volume was estimated by (1-hematocrit) x 
(a + [b x weight in kg]) where a = 1530 for men and 864 for women, and b = 41 for men and 
47.9 for women, respectively.[11] 
Echocardiography 
Subjects were studied on their chronic medications in a hemodynamically stable 
state. As loading conditions can change during an inter-dialytic interval, all hemodialysis 
patients were studied the day before dialysis session. Echocardiographic examinations were 
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performed using commercially available ultrasound systems (iE33, Philips Medical System, 
Andover, MA; Vivid 7 dimension, GE Healthcare, Horten, Norway; or Aplio 400, TOSHIBA 
Medical Systems, Japan). The LV end-diastolic (EDV) and end-systolic (ESV) volumes, mass 
and EF were determined according to current guidelines.[12] SV was determined from the LV 
outflow dimension and pulse-Doppler, and was indexed to body surface area (SVI). Left atrial 
(LA) volume was calculated by the biapical area-length method and also indexed by body 
surface area. The early filling (E-wave), the peak late diastolic (A-wave) velocities and 
deceleration time were obtained from transmitral flow. The peak systolic (s′), early diastolic 
(e′) and late diastolic (a′) mitral annular velocities were recorded at the septal annulus. The 
ratio of early mitral diastolic inflow velocities to early diastolic mitral annular velocity (E/e′) 
was calculated. Systolic and diastolic BPs were measured during echocardiographic 
examination and end-systolic BP (0.9 × systolic BP) was calculated as previously 
described.[13] Arterial afterload was determined by effective arterial elastance (Ea: 
end-systolic BP/SV [the slope of the blue line in Figure 1]) and SVR index (SVRI: mean BP × 
79.9/cardiac index). Total arterial compliance was assessed by the ratio of SV to pulse 
pressure. Load-independent contractility was assessed using modified single-beat method 
end-systolic elastance (Ees: determined from BP, SV, and pre-ejection and total systolic 
periods determined on LV outflow Doppler, EF, and an estimated normalized ventricular 
elastance at arterial end-diastole [the slope of the red line in Figure 1]), preload recruitable 
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stroke work (PRSW: determined from product of peak volumetric ejection rate from LV 
outflow Doppler and systolic BP, and EDV), and peak power index (PWRI: determined from 
product of peak volumetric ejection rate from LV outflow Doppler, systolic BP, and EDV).[13, 
14] In the pressure-volume loop concept, stroke work is the area surrounded by the 
pressure-volume loop (light blue area in Figure 1), and equals to the actual external work 
performed by the heart. By contrast, potential energy is the area surrounded by the 
end-systolic pressure-volume relationship line, isovolumic relaxation phase of the 
pressure-volume loop, and volume axis (x-axis) (orange area in Figure 1), and it reflects 
energy loss that does not participate in ejection of blood into the aorta. The pressure-volume 
area (PVA) is the sum of the stroke work and potential energy, and has been shown to 
correlate linearly with myocardial oxygen consumption.[15, 16] The ratio of PVA to SV 
represents cardiac energy costs to produce blood flow. We estimated PVA as previously 
reported.[17] An experienced echocardiologist analyzed all echocardiographic 
measurements (MO). 
Statistical analysis 
All continuous variables are presented as mean ± SD unless otherwise specified.  
Between groups differences were compared by chi-square, ANOVA, or Kruskal-Wallis test, 
with Tukey’s test or Steel-Dwass test for multiple comparisons. Multivariable linear regression 
analysis was used to adjust for baseline group differences. Two-sided p <0.05 was accepted 
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as statistical significance. All data were analyzed using SPSS version 23.0 (SPSS Inc., 
Chicago, IL). 
 
Results 
Clinical Characteristics 
Of hemodialysis patients, 30 patients (13%) met criteria for elevated output.  Age, 
sex, body mass index were similar across 3 groups (Table 1). There were no significant 
differences in dialysis duration, the proportion of causes of ESRD, or ultrafiltration volume 
between hemodialysis patients with normal and elevated output. Compared with controls, 
patients on dialysis displayed higher prevalence of hypertension and diabetes, lower 
hemoglobin levels, and greater estimated plasma volume.  
Relationships of Cardiac Output with Contractility, Afterload, and Preload.     
Table 2 shows comparisons of cardiovascular structure and function among 3 
groups. By definition, hemodialysis patients with elevated output displayed higher CI 
compared to those with normal output and controls. The increased CI in patients with high 
output was caused by both higher heart rate and SVI. As compared to hemodialysis patients 
with normal output and controls, those with elevated output had enhanced LV contractility 
(greater PRSW, PWRI, and s’ velocity) and decreased systemic arterial afterload (lower SVRI 
and Ea and higher total arterial compliance), with more than 36% lower SVRI. Compared to 
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control subjects, EDV was larger in hemodialysis patients with normal output and elevated 
output by 8% and 14% (p=0.06), respectively, but similar between the groups. Each of these 
components was related to greater CO (Figure 3, total arterial compliance r=0.47, p<0.001, s’ 
r=0.34, p<0.001, and end-diastolic volume r=0.31, p<0.001).  These data suggest that the 
increased CO in hemodialysis patients was driven by decreased SVR, enhanced ventricular 
contractility, larger ventricular preload (EDV), and tachycardia. Higher mitral A-wave and a’ 
velocity in the high output patients suggest that enhancement in atrial contraction was the 
main intra-cardiac mechanism which augmented LV filling and thus CO. 
Contributions of Anemia and Fluid Retention to High Output States 
More than 60% of patients with high output hemodialysis (n=19) had hemoglobin 
levels < 11.0 g/dl. Hemoglobin levels were directly correlated with SVRI (Figure 4A, r=0.38, 
p<0.001) and inversely correlated with heart rate (r=-0.22, p<0.0001), PWRI (-0.30, p<0.001), 
and thus CO (Figure 4B, r=-0.41, p<0.001). Both estimated plasma volume and inter-dialytic 
weight gain varied directly with EDV (Figure 4C, r=0.42 and r=0.32, both p<0.001) and CO 
(Figure 4D, r=0.41 and r=0.24, both p<0.001). Furthermore, SVRI and hemoglobin levels 
were independently associated with CO and CI (both p<0.001). These data suggest that 
anemia also increases CO by decreasing SVR, enhancing contractility, and/or increasing 
heart rate while plasma volume expansion does so by solely increasing ventricular preload.   
Relationships of Cardiac Output with LV Morphology, Dysfunction, and Myocardial 
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Energetics 
Compared with control subjects, both hemodialysis groups displayed greater LV 
mass index and impaired diastolic function, with higher mitral inflow E-wave, E/e' ratio, and 
LA volume index. The increase in CO was associated with greater LV mass index (r=0.35, 
p<0.001) and LA volume index (r=0.24, p<0.001). The PVA was markedly increased in 
hemodialysis patients with high output compared with those with normal output and control 
subjects, and remained significantly higher in the high output patients than those with normal 
output after adjusting for hemoglobin levels (both p<0.001). The elevation in CO was directly 
correlated with greater PVA (Figure 5A). Furthermore, the ratio of PVA to SV was increased in 
hemodialysis patients with elevated output compared with those with normal output and 
controls (Figure 5B), suggesting a contribution of high output state not only to greater 
myocardial oxygen consumption but to increased cardiac energy costs for a given SV . 
Effects of Vasodilators on Cardiovascular Function 
As compared with controls and hemodialysis patients with normal output, those with 
elevated output were more likely to be treated with angiotensin-converting enzyme 
inhibitors/angiotensin-receptor blockers (ACEIs/ARBs), calcium channel blockers (CCBs), 
and diuretics (Table 1). This indicates that vasodilator use may be associated with increased 
CI by reducing SVR. To explore this hypothesis, we divided hemodialysis patients into 3 
groups based on vasodilator use (Supplemental table). Of hemodialysis patients, there were 
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107 subjects (45%) receiving combination vasodilator therapy (ACEI/ARB and CCB), and 63 
(27%) those receiving either ACEI/ARB or CCB, and 65 subjects (28%) not receiving either 
drug. While systolic BP, pulse pressure, LV mass index, and EDV were higher in patients 
receiving the combination vasodilator therapy, there were no differences in arterial afterload 
or CI among the groups. The combination vasodilator therapy was associated with greater 
PVA and PVA/SV ratio, but these associations did not persist after adjusting for systolic BP, 
LV mass index, or systolic BP (all p>0.7), suggesting that arterial hypertension, LV 
hypertrophy, and volume expansion but not vasodilator therapy contribute to increased 
myocardial oxygen consumption and energy cost in dialysis patients. 
 
Discussion 
This study provides the first evaluation of relationships among fluid retention, 
anemia, multiple vasodilator use, and increased CO, and determines the effects of the high 
output state on ventricular remodeling, dysfunction, and myocardial energetics in patients 
receiving hemodialysis, using noninvasive pressure-volume loop assessment. As compared 
to hemodialysis patients with normal output, those with elevated output displayed decreased 
SVR, increased ventricular contractility, and tachycardia. Lower hemoglobin levels were 
correlated with decreased SVR, greater LV contractility, and tachycardia while fluid retention 
was associated with increased LV preload (EDV), contributing to increased CO. LV mass 
 - 13 - 
 
index and diastolic function were similarly abnormal in hemodialysis patients with normal and 
elevated output but patients with high output displayed markedly increased PVA and PVA/SV 
ratio that were correlated directly with increased CO, suggesting a contribution of high output 
state to greater myocardial oxygen consumption and cardiac energy costs. In contrast, the 
combination vasodilator therapy was not associated with high output states in dialysis 
patients. These data provide new insights into the mechanisms underlying high output states 
in patients on dialysis. 
Anemia and Fluid Retention – Potential Contributors to High Output States - 
Arteriovenous shunt is a common cause of high output HF and shut-related high 
output HF is associated with substantial risk of mortality.[2] Patients on dialysis often have 
conditions that potentially increase CO, including the arteriovenous shunts, inter-dialytic fluid 
retention, renal anemia, and multiple vasodilator use. The effects of AVF on CO and 
cardiovascular system have been studied, but very little is known how other potential risks 
contribute to high output states in hemodialysis patients. In agreement with a previous 
invasive study examining various forms of high output HF,[2] the current data showed the 
increased CO in dialysis patient was related to decreased systemic arterial afterload, 
enhanced ventricular contractility, larger ventricular preload, and tachycardia, rather than the 
decreased systemic afterload alone. We further demonstrated that anemia was related to 
decreasing SVR, increasing heart rate, and enhancing myocardial contractility while fluid 
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retention correlated with increased LV preload (i.e, EDV), which contribute to high output. 
Anemia is common and associated with adverse cardiovascular outcomes in ESRD 
patients.[18] It has been reported that severe anemia (mean hemoglobin <5.0 g/dl)[19] 
decreases SVR by vasodilation (enhanced endothelium-derived relaxing factor and 
inactivation of nitric oxide) and reducing plasma viscosity, and increases heart rate to 
compensate oxygen delivery.[19-21] The negative relationship between hemoglobin levels 
and enhanced ventricular contractility may be explained by anemia-inducing catecholamine 
elevation.[22] Our data suggest that even mild to moderate anemia in dialysis patients (mean 
hemoglobin 10.6±1.0 g/dl in high output patients) relates to increases in CO.  
In the current study, EDV increased directly with increases in estimated plasma 
volume and inter-dialytic weight gain, contributing to high output states. Volume overload is 
another clinical problem in dialysis patients and an important predictor of cardiovascular and 
all-cause deaths.[23, 24] Fluid retention in dialysis patients may be related to increased 
venous return due to arteriovenous shunting and accumulation of water and sodium during 
inter-dialytic period, where ventricular preload (i.e., EDV) is increased by nearly 50%.[8] 
These data reinforce the importance of appropriate management of volume status in patients 
on dialysis. 
Effects of Increased Output on Myocardial Function  
High output states in dialysis patients can lead to structural remodeling and 
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myocardial dysfunction.[3] However, evidence supporting this highly relies on studies 
comparing changes following creation of arteriovenous shunt.[6, 7] Previous studies have 
demonstrated that AVF creation leads to increases in LV mass, dilation of cardiac chambers 
(LV, RV, and LA), and worsening LV diastolic function, with increase in CO.[6, 7] In contrast, 
ligation of AVF was associated with LV reverse remodeling.[25, 26] In line with these results, 
we found direct correlation among increased CO, LV hypertrophy, and LA dilation. It is 
believed that the adverse remodeling and myocardial dysfunction caused by increased CO 
may increase myocardial oxygen demands, contributing to subsequent morbidity and 
mortality in patients with hemodialysis. We show for the first time that hemodialysis patients 
with high output had markedly increased myocardial oxygen consumption that was correlated 
directly with increased CO. This is consistent with prior studies.[27, 28] Buckberg et al. have 
reported that the formation of arteriovenous fistula in dogs increases myocardial oxygen 
demand and decreases oxygen supply, resulting in subendocardial ischemia.[27] In a small 
case series, Savage et al. have shown that myocardial oxygen consumption increases after 
creation of AVF while oxygen supply remains unchanged.[28] We further demonstrated that 
PVA/SV ratio was elevated in hemodialysis patients with elevated output. These data 
suggest that the high output state in dialysis patients is related not only to greater myocardial 
oxygen consumption but to increased cardiac energy costs to provide blood flow. 
Arteriovenous shunt-related high output HF is associated with substantial risk of death.[2] 
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Further longitudinal study is required to determine whether increased myocardial 
consumption and energy costs predict adverse outcomes in this population.  
Clinical Implications  
The current data have several important clinical implications. Vasodilators are a 
cornerstone in the management of hypertension and multiple vasodilators are often required 
to achieve optimal BP control in dialysis patients.[29] High output patients were more likely to 
be receiving vasodilators, forming the hypothesis that multiple vasodilator use would cause 
high output states in dialysis patients. However, we found that the combination vasodilator 
therapy (ACEI/ARB and CCB) was not associated with increased CI or excessive 
vasodilation.  
The severity of hypertension in dialysis patients is attributed partly to volume 
expansion, making the management of hypertension more challenging. Despite the multiple 
vasodilator use, systolic BP was markedly elevated (~160 mmHg) in patients who receiving 
both ACEI/ARB and CCB. Because arterial afterload and contractility were similar among 
groups, the high systolic BP was driven by increased flow (i.e., CO) owing to fluid expansion. 
Our data indicate that reduction of EDV may be required to improve not only BP control but 
myocardial energy cost in this group of patients. It is often difficult to evaluate fluid status in 
patients on dialysis. The echocardiographic pressure-volume loop assessment provides 
information on systemic arterial afterload, ventricular preload, LV contractility, CO, and 
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myocardial energetics. Although the clinical benefits of treatment of hypertension in 
hemodialysis patients have not been established,[29] our data suggest that the noninvasive 
approach may be useful in the management of hypertension for patients on dialysis.  
There is no proven therapy for high output HF. The treatment in dialysis patients is 
often challenging because it sometimes requires interventions to shunts at the expense of 
loss of vascular access.[30-32] We demonstrate that anemia and fluid retention in 
hemodialysis patients are important contributors to high output states. These data reinforce 
the importance of evaluation for anemia and volume status as well as AVF blood flow when 
high output HF is suspected.[3] Further studies are needed to determine whether therapies 
targeting anemia and fluid retention would improve hemodialysis patients with high output HF. 
Limitations 
This study has several limitations. This study was performed in two Japanese tertiary 
centers and as such has selection bias. Subjects were not studied invasively because of the 
challenges posed by the risk of invasive measurements. Therefore, we obtained 
pressure-volume relationship using noninvasive echocardiographic techniques. These 
noninvasive parameters have been well validated and have been applied to dialysis 
populations.[8, 9] Given the complexity of interpretation, we did not extend dose or types of 
vasodilators in our analyses. However, this is the first study evaluating the effect of high 
output on cardiovascular function in hemodialysis patients. This was cross-sectional study 
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and future prospective studies should be warranted to determine prognostic values of 
pressure-volume loop parameters in patients on dialysis 
Conclusions 
Decreased systemic vascular resistance, increased ventricular contractility and 
preload, and tachycardia contribute to high output states in patients on dialysis. Anemia 
increases CO by decreasing SVR, enhancing ventricular contractility, and increasing heart 
rate while fluid retention does so by increasing ventricular preload. The increase in CO is 
associated with greater myocardial oxygen consumption and cardiac energy costs. These 
data provide new insights into the mechanisms underlying high output states in patients on 
dialysis.  
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Figure legends 
Figure 1. Pressure-volume loop relationship. Ea, effective arterial elastance; EDV, 
end-diastolic volume; Ees, end-systolic elastance; ESP, end-systolic pressure; ESV, 
end-systolic volume; and V0, left ventricular (LV) volume at LV pressure of 0 mmHg. 
 
Figure 2. Correlations between cardiac output (CO) and indicators of arterial afterload and 
LV contractility. HD, hemodialysis; PRSW, preload recruitable stroke work; PWRI, peak power 
index; SVRI, systemic vascular resistance index; and other abbreviations as in Figure 1. 
 
Figure 3. (A-B) Lower hemoglobin levels were correlated with decreased SVRI and 
increased CO. (C-D) Estimated plasma volume was directly correlated with greater EDV and 
CO. Abbreviations as in Figures 1 and 2. 
 
Figure 4. (A) The increase in CO was directly correlated with greater pressure-volume area 
(PVA). (B) The ratio of pressure-volume area to SV was markedly increased in hemodialysis 
patients with elevated output as compared to those with normal output and controls. These 
data suggest that high output states lead to increases in myocardial oxygen consumption and 
energy costs. *p<0.05 vs. controls and †p<0.05 vs. hemodialysis patients with normal output. 
(C-D) Hemodialysis patients receiving both angiotensin-converting enzyme 
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inhibitor/angiotensin-receptor blocker (ACEI/ARB) and calcium channel blocker (CCB) 
displayed greater CO and PVA as compared to those receiving either ACEI/ARB or CCB and 
those not receiving either. *p<0.05 vs. hemodialysis patients not receiving either ACEI/ARB 
or CCB and †p<0.05 vs. hemodialysis patients receiving either ACEI/ARB or CCB. 
Abbreviations as in Figures 2-3. 
 
